Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H24O2 |
Molecular Weight | 272.382 |
Optical Activity | ( + ) |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C(O)C=C4
InChI
InChIKey=VOXZDWNPVJITMN-ZBRFXRBCSA-N
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
Molecular Formula | C18H24O2 |
Molecular Weight | 272.382 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11250930https://pubchem.ncbi.nlm.nih.gov/compound/222757http://www.drugbank.ca/drugs/DB00783Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020375s027lbl.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11250930https://pubchem.ncbi.nlm.nih.gov/compound/222757http://www.drugbank.ca/drugs/DB00783
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020375s027lbl.pdf
Estradiol an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. In humans, it is produced primarily by the cyclic ovaries and the placenta. It is also produced by the adipose tissue of men and postmenopausal women. The 17-alpha-isomer of estradiol binds weakly to estrogen receptors (receptors, estrogen) and exhibits little estrogenic activity in estrogen-responsive tissues. Estradiol enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estradiol is used for the treatment of urogenital symptoms associated with post-menopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). Estradiol is marketed under the brand name Climara (among others), indicated for: the treatment of moderate to severe vasomotor symptoms due to menopause, treatment of symptoms of vulvar and vaginal atrophy due to menopause, treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure and prevention of postmenopausal osteoporosis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25231731https://books.google.ru/books?id=L4YQ50SbBnsC&pg=PA223&lpg=PA223&dq=estradiol+cross+blood+brain+barrier&source=bl&ots=1XAPNkXVXI&sig=_VCp7qIuyiwBe9cGGJDMvmdR8zg&hl=ru&sa=X&ved=0ahUKEwjjk6vD8r7PAhWCFywKHU3xD8c4ChDoAQg4MAU#v=onepage&q=estradiol%20cross%20blood%20brain%20barrier&f=false, retrieved from
Curator's Comment: Estrogen Effects in Psychiatric Disorders
Niels Bergemann,Anita Riecher-Rössler, p.223
Originator
Sources: http://www.google.ru/patents/US2054271https://books.google.ru/books?id=_J2ti4EkYpkC&pg=PA1478&lpg=PA1478&dq=ESTRADIOL+year+introduced&source=bl&ots=N5lzH8ALwu&sig=V9zqvrxhsCojxBpoWmAWSN7AXcc&hl=ru&sa=X&ved=0ahUKEwj975678L7PAhVGXSwKHb5cBkUQ6AEISDAH#v=onepage&q=ESTRADIOL%20year%20introduced&f=false, retrieved from Pharmaceutical Manufacturing Encyclopedia, 3rd Edition : William Andrew Publishing, p.1475
Curator's Comment: Introduced in 1952
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P08842 Gene ID: 412.0 Gene Symbol: STS Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11250930 |
|||
Target ID: CHEMBL206 Sources: http://www.drugbank.ca/drugs/DB00783 |
0.0084 nM [EC50] | ||
Target ID: CHEMBL242 Sources: http://www.drugbank.ca/drugs/DB00783 |
1.4 nM [EC50] | ||
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16309907 |
19.1 nM [IC50] | ||
Target ID: CHEMBL206 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/222757 |
0.13 nM [Ki] | ||
Target ID: CHEMBL242 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/222757 |
0.09 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CLIMARA Approved UseClimara is an estrogen indicated for:
•Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause
•Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause
•Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure
•Prevention of Postmenopausal Osteoporosis Launch Date1974 |
|||
Preventing | CLIMARA Approved UseClimara is an estrogen indicated for:
•Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause
•Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause
•Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure
•Prevention of Postmenopausal Osteoporosis Launch Date1974 |
|||
Primary | CLIMARA Approved UseClimara is an estrogen indicated for:
•Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause
•Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause
•Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure
•Prevention of Postmenopausal Osteoporosis Launch Date1974 |
|||
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.7 pg/mL |
0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
ESTRADIOL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
|
92 pg/mL |
0.05 mg 1 times / day multiple, topical dose: 0.05 mg route of administration: Topical experiment type: MULTIPLE co-administered: |
ESTRADIOL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
236 pg × h/mL |
0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
ESTRADIOL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10 h |
0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
ESTRADIOL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
|
1.75 h |
0.05 mg 1 times / day multiple, topical dose: 0.05 mg route of administration: Topical experiment type: MULTIPLE co-administered: |
ESTRADIOL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/abs/10.1021/mp900077q Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
minor | |||
Page: - |
minor | |||
Page: - |
minor | |||
Page: - |
minor | |||
Page: - |
minor | |||
Page: - |
minor | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
yes [Km 7 uM] | |||
Page: - |
yes | |||
Page: - |
yes | |||
Sources: https://www.pnas.org/content/93/18/9776.short Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of estradiol benzoate on the proliferation of osteogenic cells in fetal rat fibulae cultured in vitro. | 1978 Mar |
|
An increase of pituitary 3', 5' cyclic adenosine monophosphate produced by estradiol benzoate in vitro: possible implication of this increase in the secretion of luteinizing hormone. | 1978 May |
|
Sulfation of estrone and 17 beta-estradiol in human liver. Catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase. | 1992 May-Jun |
|
Estradiol prevents and testosterone promotes Fas-dependent apoptosis in CD4+ Th2 cells by altering Bcl 2 expression. | 1999 |
|
Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia. | 1999 Apr |
|
Differential regulation of c-fos expression in estrogen-induced hamster renal tumors compared with kidney not due to creation of an estrogen-response element by point mutation in the gene's flanking sequence. | 1999 Apr |
|
Growth stimulation of a rat pituitary cell line MtT/E-2 by environmental estrogens in vitro and in vivo. | 1999 Aug |
|
Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems. | 1999 Aug |
|
Methoxychlor stimulates estrogen-responsive messenger ribonucleic acids in mouse uterus through a non-estrogen receptor (non-ER) alpha and non-ER beta mechanism. | 1999 Aug |
|
Lack of mutations in DNA polymerase beta of estradiol-induced hamster kidney tumors: sequence of hamster DNA polymerase beta cDNA. | 1999 Aug |
|
Inhibitory effect of natural and environmental estrogens on thymic hormone production in thymus epithelial cell culture. | 1999 Dec |
|
Rapid inhibition of rat brain mitochondrial proton F0F1-ATPase activity by estrogens: comparison with Na+, K+ -ATPase of porcine cortex. | 1999 Feb 26 |
|
Low-dose bioactivity of xenoestrogens in animals: fetal exposure to low doses of methoxychlor and other xenoestrogens increases adult prostate size in mice. | 1999 Jan-Mar |
|
Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium. | 1999 Jul 1 |
|
Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. | 1999 Jul 13 |
|
Endometrial cancer after combined hormone replacement therapy. | 1999 Mar 15 |
|
Sex steroids and odorants modulate gonadotropin-releasing hormone secretion in primary cultures of human olfactory cells. | 1999 Nov |
|
The aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT) heterodimer interacts with naturally occurring estrogen response elements. | 1999 Nov 25 |
|
Steroid feedback on gonadotropin release and pituitary gonadotropin subunit mRNA in mice lacking a functional estrogen receptor alpha. | 1999 Oct |
|
Effect of chlorinated hydrocarbons on expression of cytochrome P450 1A1, 1A2 and 1B1 and 2- and 4-hydroxylation of 17beta-estradiol in female Sprague-Dawley rats. | 2000 Aug |
|
High concentrations of bisphenol A induce cell growth and prolactin secretion in an estrogen-responsive pituitary tumor cell line. | 2000 Feb 1 |
|
The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. | 2000 Jan |
|
The aryl hydrocarbon receptor interacts with estrogen receptor alpha and orphan receptors COUP-TFI and ERRalpha1. | 2000 Jan 1 |
|
Intrinsic alcohol dehydrogenase and hydroxysteroid dehydrogenase activities of human mitochondrial short-chain L-3-hydroxyacyl-CoA dehydrogenase. | 2000 Jan 1 |
|
Atheroprotective effect of estriol and estrone sulfate on human vascular smooth muscle cells. | 2000 Jan-Feb |
|
Estradiol and pesticide methoxychlor do not exhibit additivity or synergism in the reproductive tract of adult ovariectomized mice. | 2000 Jul 28 |
|
Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate Pregnane X receptor-mediated transcription. | 2000 Mar |
|
Assaying estrogenicity by quantitating the expression levels of endogenous estrogen-regulated genes. | 2000 May |
|
Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene. | 2000 Nov |
|
Relative binding affinity does not predict biological response to xenoestrogens in rat endometrial adenocarcinoma cells. | 2000 Oct |
|
Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin in mouse uterus: critical role of the aryl hydrocarbon receptor in stromal tissue. | 2000 Oct |
|
Repression of chick multidrug resistance-associated protein 1 (chMRP1) gene expression by estrogen. | 2000 Oct 31 |
|
NADPH- and hydroperoxide-supported 17beta-estradiol hydroxylation catalyzed by a variant form (432L, 453S) of human cytochrome P450 1B1. | 2000 Sep |
|
Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo. | 2001 Apr |
|
Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ERalpha and ERbeta ) at AP-1 sites. | 2001 Feb 9 |
|
Effects of follicle-stimulating hormone with and without luteinizing hormone on serum hormone concentrations, follicle growth, and intrafollicular estradiol and aromatase activity in gonadotropin-releasing hormone-immunized heifers. | 2001 Jan |
|
Regulation and role of vascular endothelial growth factor in the corpus luteum during mid-pregnancy in rats. | 2001 Jan |
|
Pregnancy stimulates secretion of adrenocorticotropin and nitric oxide from peripheral bovine lymphocytes. | 2001 Jan |
|
Stimulatory effect of clofibrate and gemfibrozil administration on the formation of fatty acid esters of estradiol by rat liver microsomes. | 2001 Jan |
|
Influence of gender and sex hormones on nicotine acute pharmacological effects in mice. | 2001 Jan |
|
Heat-shock factor-1, steroid hormones, and regulation of heat-shock protein expression in the heart. | 2001 Jan |
|
Evaluation of an EIA method for measuring serum levels of the estrogen metabolite 2-hydroxyestrone in adults. | 2001 Jan |
|
Neuroprotection by estradiol. | 2001 Jan |
|
Affinity labeling of rat glutathione S-transferase isozyme 1-1 by 17beta -iodoacetoxy-estradiol-3-sulfate. | 2001 Jan 19 |
|
Hormone binding by protein disulfide isomerase, a high capacity hormone reservoir of the endoplasmic reticulum. | 2001 Jan 5 |
|
Acquisition of Lubrol insolubility, a common step for growth hormone and prolactin in the secretory pathway of neuroendocrine cells. | 2001 Jan 5 |
|
In vivo regulation of syndecan-3 expression in the rat uterus by 17 beta-estradiol. | 2001 Jan 5 |
|
The unusual binding properties of the third distinct teleost estrogen receptor subtype ERbetaa are accompanied by highly conserved amino acid changes in the ligand binding domain. | 2004 Jun |
|
Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. | 2007 Mar 10 |
|
Changes in Expression of Connexin Isoforms in the Caudal Epididymis of Adult Sprague-Dawley Rats exposed to Estradiol Benzoate or Flutamide at the Neonatal Age. | 2016 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Estradiol benzoate is not approved by the FDA for use in humans in the United States.
Unknown
Route of Administration:
Unknown
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21273638
Estradiol-3-sulfate (E2SO4) infused intracerebroventricularly (icv) significantly increased plasma adrenocorticotropic hormone (ACTH) and cortisol concentrations. All minipumps in the treated fetuses were filled with E2SO4 in the vehicle (water) and minipumps in the control fetuses were filled with vehicle only. These minipumps deliver a constant infusion of 5 μL/h; the concentration of E2SO4 in infusates was therefore 8.33 μg/μL. It was concluded, that E2SO4 had complex actions on the fetal brain, which might involve deconjugation by steroid sulfatase. But that the net result of direct E2SO4 icv infusion was more complex than could be accounted for by infusion of E2 alone.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:14:36 GMT 2023
by
admin
on
Fri Dec 15 15:14:36 GMT 2023
|
Record UNII |
4TI98Z838E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
35384-7
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
34290-7
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
34286-5
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
12595-5
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
2239-2
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
WHO-ATC |
G03CA03
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
WHO-VATC |
QG03CA03
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
CFR |
21 CFR 522.840
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
83097-6
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
2240-0
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
14715-7
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
15062-3
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
12214-3
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
34288-1
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
FDA ORPHAN DRUG |
231706
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
WHO-VATC |
QG03CA53
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
25401-1
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
CFR |
21 CFR 310.527
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
WHO-VATC |
QG03AB08
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
NDF-RT |
N0000011402
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
WHO-ATC |
G03AA14
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
13883-4
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
2246-7
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
WHO-VATC |
QG03AA14
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
CFR |
21 CFR 556.240
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
72873-3
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
34287-3
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
55857-7
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
35207-0
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
21263-9
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LIVERTOX |
372
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
2243-4
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
2245-9
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
2238-4
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
31176-1
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
WHO-ATC |
G03CA53
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
WHO-ATC |
G03AB08
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
14960-9
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
2241-8
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
IOA (WITHDRAWN: CONTRACEPTION)
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
NDF-RT |
N0000000100
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
12213-5
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
34291-5
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
CFR |
21 CFR 522.2477
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
NDF-RT |
N0000175825
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
44730-0
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
34289-9
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
CFR |
21 CFR 862.1430
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
CFR |
21 CFR 862.1260
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
NCI_THESAURUS |
C2293
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
13736-4
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
55858-5
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
83096-8
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
2242-6
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
||
|
LOINC |
2244-2
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1013
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
200-023-8
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
ESTRADIOL
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
Estradiol
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
DB00783
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
SUB96040
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
23965
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
m5028
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
Estradiol (medication)
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
D004958
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
20293
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
DTXSID0020573
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
406
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
C478
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL135
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
1057
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
50-28-2
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
100000091739
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
9895
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
4TI98Z838E
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
16469
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
1250008
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
SUB07242MIG
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
4TI98Z838E
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
4083
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB21195
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
3589
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY | |||
|
5757
Created by
admin on Fri Dec 15 15:14:37 GMT 2023 , Edited by admin on Fri Dec 15 15:14:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
SOLVATE->ANHYDROUS | |||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET -> AGONIST |
BINDING
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SUBSTANCE->BASIS OF STRENGTH |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
Binding Assay
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
E2 is then extensively metabolized to estrone (E1) (15%), estrone sulfate (E1S) (65%), and other compounds.
|
||
|
METABOLITE -> PARENT |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
E2 is then extensively metabolized to estrone (E1) (15%), estrone sulfate (E1S) (65%), and other compounds.
|
||
|
METABOLITE LESS ACTIVE -> PARENT |
IN-VITRO
|
||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
IN-VIVO
URINE
|
||
|
PARENT -> METABOLITE |
Metabolite produced by hydrolysis. Estramustine,s primary mechanism of antineoplastic action is inhibition of mitosis.
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
PARENT -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
IN-VITRO
Scientific Literature
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
ESTRADIOL VALERATE |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
ESTRADIOL VALERATE |
|
||